Diet, fatty acids, and regulation of genes important for heart disease

被引:33
作者
Vanden Heuvel J.P. [1 ]
机构
[1] Department of Veterinary Sciences, Ctr. Molec. Toxicol./Carcinogenesis, Pennsylvania State University, University Park, PA 16802
关键词
Conjugate Linoleic Acid; Peroxisome Proliferator Activate Receptor; Conjugate Linoleic Acid Isomer; Fatty Acid Receptor; Hepatic Peroxisome Proliferation;
D O I
10.1007/s11883-004-0083-9
中图分类号
学科分类号
摘要
Diets rich in omega-3 polyunsaturated fatty acids (n-3 PUFAs), such as alpha-linoleic acid, eicosapentaenoic acid, and docosahexaenoic acid, are associated with decreased incidence and severity of coronary heart disease. Similarly, conjugated linoleic acids (CLAs), which are found in meat and dairy products, have beneficial effects against atherosclerosis, diabetes, and obesity. The effects of n3-PUFAs and CLAs are in contrast to fatty acids with virtually identical structures, such as linoleic acid and arachidonic acid (ie, n-6 PUFAs). This article discusses the possibility that cognate receptors exist for fatty acids or their metabolites that are able to regulate gene expression and coordinately affect metabolic or signaling pathways associated with coronary heart disease. Three nuclear receptors are emphasized as fatty acid receptors that respond to dietary and endogenous ligands: peroxisome proliferator activated receptors, retinoid X receptors, and liver X receptors. Copyright © 2004 by Current Science Inc.
引用
收藏
页码:432 / 440
页数:8
相关论文
共 85 条
[41]  
Barbier O., Torra I.P., Duguay Y., Et al., Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 22, pp. 717-726, (2002)
[42]  
Duval C., Chinetti G., Trottein F., Et al., The role of PPARs in atherosclerosis, Trends Mol. Med., 8, pp. 422-430, (2002)
[43]  
Fruchart J.C., Staels B., Duriez P., PPARS, metabolic disease and atherosclerosis, Pharmacol. Res., 44, pp. 345-352, (2001)
[44]  
Vosper H., Khoudoli G.A., Graham T.L., Palmer CN: Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis, Pharmacol. Ther., 95, pp. 47-62, (2002)
[45]  
Kersten S., Desvergne B., Wahli W., Roles of PPARs in health and disease, Nature, 405, pp. 421-424, (2000)
[46]  
Escher P., Wahli W., Peroxisome proliferator-activated receptors: Insight into multiple cellular functions, Mutat. Res., 448, pp. 121-138, (2000)
[47]  
Rocchi S., Auwerx J., Peroxisome proliferator-activated receptor-gamma: A versatile metabolic regulator, Ann. Med., 31, pp. 342-351, (1999)
[48]  
Schoonjans K., Staels B., Auwerx J., The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation, Biochim. Biophys. Acta, 1302, pp. 93-109, (1996)
[49]  
Tontonoz P., Hu E., Graves R.A., Et al., mPpar gamma 2: Tissue-specific regulator of an adipocyte enhancer, Genes Dev., 8, pp. 1224-1234, (1994)
[50]  
Tontonoz P., Nagy L., Alvarez J.G., Et al., PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL, Cell, 93, pp. 241-252, (1998)